EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, RemeGen Co's enterprise value is HK$28,035.2 Mil.
RemeGen Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$734.8 Mil. Therefore, RemeGen Co's EV-to-Revenue for today is 38.15.
The historical rank and industry rank for RemeGen Co's EV-to-Revenue or its related term are showing as below:
HKSE:09995'
s EV-to-Revenue Range Over the Past 10 Years
Min: 15.8 Med: 40.59 Max: 126.92
Current: 38.15
During the past 6 years, the highest EV-to-Revenue of RemeGen Co was 126.92. The lowest was 15.80. And the median was 40.59.
HKSE:09995's EV-to-Revenue is ranked worse than 75.07% of 1039
companies
in the Biotechnology industry
Industry Median: 8.37
vs HKSE:09995: 38.15
As of today (2024-05-12), RemeGen Co's stock price is HK$31.40.
RemeGen Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.37. Therefore, RemeGen Co's PS Ratio for today is 23.00.
RemeGen Co EV-to-Revenue Historical Data
The historical data trend for RemeGen Co's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RemeGen Co's EV-to-Revenue
For the Biotechnology subindustry, RemeGen Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where RemeGen Co's EV-to-Revenue falls into.
RemeGen Co's current Enterprise Value is HK$28,035.2 Mil.
RemeGen Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$734.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co's share price for today is HK$31.40.
RemeGen Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$1.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of RemeGen Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09995 has been successfully added to your 